299 related articles for article (PubMed ID: 33569340)
1. Neoadjuvant treatment of stage IIIA-N2 in
Reyes R; Reguart N
Transl Lung Cancer Res; 2021 Jan; 10(1):607-621. PubMed ID: 33569340
[TBL] [Abstract][Full Text] [Related]
2. Early-stage anaplastic lymphoma kinase (
Chen MF; Chaft JE
Transl Lung Cancer Res; 2023 Feb; 12(2):337-345. PubMed ID: 36895922
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Zhai H; Zhong W; Yang X; Wu YL
Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
de Scordilli M; Michelotti A; Bertoli E; De Carlo E; Del Conte A; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806230
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Mielgo-Rubio X; Martín M; Remon J; Higuera O; Calvo V; Jarabo JR; Conde E; Luna J; Provencio M; De Castro J; López-Ríos F; Hernando-Trancho F; Couñago F
Future Oncol; 2021 Oct; 17(30):4011-4025. PubMed ID: 34337973
[TBL] [Abstract][Full Text] [Related]
7. A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer.
Hopson MB; Rashdan S
Front Oncol; 2024; 14():1373388. PubMed ID: 38601764
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2)
Xiong L; Li R; Sun J; Lou Y; Zhang W; Bai H; Wang H; Shen J; Jing B; Shi C; Zhong H; Gu A; Jiang L; Shi J; Fang W; Zhao H; Zhang J; Wang J; Ye J; Han B
Oncologist; 2019 Feb; 24(2):157-e64. PubMed ID: 30158288
[TBL] [Abstract][Full Text] [Related]
9. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.
Zhong W; Yang X; Yan H; Zhang X; Su J; Chen Z; Liao R; Nie Q; Dong S; Zhou Q; Yang J; Tu H; Wu YL
J Hematol Oncol; 2015 May; 8():54. PubMed ID: 25981169
[TBL] [Abstract][Full Text] [Related]
11. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
12. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
13. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
Leonetti A; Minari R; Boni L; Gnetti L; Verzè M; Ventura L; Musini L; Tognetto M; Tiseo M
Clin Lung Cancer; 2021 Sep; 22(5):473-477. PubMed ID: 33762169
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
Deslypere G; Gullentops D; Wauters E; Vansteenkiste J
Ther Adv Med Oncol; 2018; 10():1758835918772810. PubMed ID: 29774061
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
Liu J; Amini A; Govindarajan A; Abuali T; Mambetsariev I; Massarelli E; Villaflor V; Villalona-Calero M; West H; Williams T; Salgia R
JCO Precis Oncol; 2023 Sep; 7():e2200445. PubMed ID: 37656950
[TBL] [Abstract][Full Text] [Related]
17. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
18. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
Mendoza DP; Stowell J; Muzikansky A; Shepard JO; Shaw AT; Digumarthy SR
Clin Lung Cancer; 2019 Sep; 20(5):339-349. PubMed ID: 31164317
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy.
Tazza M; Metro G
J Thorac Dis; 2017 Oct; 9(10):4064-4069. PubMed ID: 29268417
[TBL] [Abstract][Full Text] [Related]
20. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
